The anti-congestive action of fx prostate & bladder is based on the inhibition of the prostaglandin and leukotriene biosynthesis, the activities of both the 5-lipoxygenase and cyclo-oxygenase enzymes are markedly reduced and the arachidonic acid.



The inhibition of the arachidonic acid cascade by Graminaceae pollen extract prevents intraprostatic tissue edema and fibrosis, and leads to a significant reduction in clinical symptoms (Literature: 1-6, 8).

Inhibition of prostaglandin and leukotriene biosynthesis



Chart: fx prostate & bladder inhibits the cyclo-oxygenase and the 5-lipoxygenase and thus reduces the biosynthesis of prostaglandins and leukotrienes and arachidonic acid.

Enlargement and congestion of the prostate gland are the principal factors responsible for the obstructive symptoms in patients with BPH. Histological examination of the gland shows that interstitial edema with an inflammatory cell infiltrate is a major contributory factor. The anti-inflammatory action of fx prostate & bladder is therefore, a pharmacologically effective therapeutic principle.

Anti-congestive effect of fx prostate & bladder

The anti-congestive effect of Flower Pollen Extract leads to a marked reduction in prostate volume in stage II and III of BPH (Vahlensieck).

Shrinkage of prostate.

       

Images: Transrectal ultra sonography of the prostate before and after 6 months treatment with Flower Pollen Extract. Marked reduction of the circumference, transverse and a-p diameter of the prostate (Literature: 4).

Voiding Difficulties in BPH
 
In BPH patients the decongestive effect of fx prostate & bladder leads to a lasting improvement of voiding difficulties. High response rates are also obtained in one of the main symptoms of BPH, namely nocturia.

Residual urine decreases, on average, by 47%; the superiority of Flower Pollen Extract in comparison with placebo is significant.

Significant superiority of fx prostate & bladder

Parameter	Active Drug	Placebo
Clinical symptom
	Seeing significant improvement (%)
Nocturia	66.7	37.2
Frequency	61.9	37.0
	Becoming symptom-free (%)
Frequency	45.2	15.2
Sensation of incomplete emptying	38.2	3.8
Urodynamics
Residual urine	Volume
-- Before therapy (ml: x ± s)	54.5 ± 24.9	51.9 ± 32.0
-- After therapy (ml: x ± s)	28.9 ± 19.7	44.9 ± 28.6
-- Reduction (%)	47.0	13.5
Global assessment of overall outcome by Physician	Very Good 37.2%	11.4%

Table: Results of the double blind study: Significant differences is favor of Flower Pollen Extract clinical symptomatology and urodynamics (Literature: 2).

Urodynamics in BPH

The anti-congestive effect of the Graminaceae pollen extract leads to marked improvement of the difficulties of micturition. The residual urine volume decreases significantly (Literature: 1 2, 4). The therapeutic evaluation confirms the superiority of the Graminaceae pollen therapy (Literature: 1).

Reduction of the residual urine volume.



Graph: Course of the residual urine volume (ml) in BHP stage Ill. Significantly different and con ti9uous decrease in the residual urine volume under treatment with pollen extract (Literature: 1).

Positive evaluation of therapeutic response.



Graph: Significantly better evaluation of therapeutic and patient in the pollen extract group (Literature: 1) response by clinician.

Literature:

Graminaceae Pollen Extract Studies:

1. Becker H Ebeling L, Konservative Therapie der benignen Prostata Hyperplasie (BPH). Urologe B28 301-3061988
2. Becker H, Ebeling L, Phytotherapre der BPH. Egebnisse einei kontrotierten Verlaufsstudie Urologe B31, 113-116 1991
3. Buck AC et al. Treatment of chronic prostatitis and prostatodynia with pollen-extract British Journal of Urology 64. 496-499, 1989
4. Buck AC et al.. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract A double- blind, placebo-controlled study. British Journal of Urology. 66, 398-404,1990
5. Ebeling L The therapeutic results of defined pollen extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. In Schmiedt E, Aiken JE. Bauer HW (eds) Therapy of Prostatitis. Zuckschwerdt Verlag MOnchen S 154- 1601986
6. Leander G. A preliminary investigation on the therapeutic effect of Pollen Extract in chronic prostatovesiculitis Svenska Ldkartidningen 59(45), 3296,1962
7. Loschen G, Ebeling L, Hemmung der Arachidons,;—ure-Kaskade durch einen Extrakt aus Roggenpollen Arzneimittelfor schung41 (1), 162 167 1991
8. Rugendorff E et al. Results of Treatment with Pollen Extract in Prostatodynia and Chronic Prostatitis British Journal of Urol ogy 1992 (in press)

Further Literature:

9. Barbalias GA et al . Prostatodynia Clinical and urodynamic characteristics Journal of Urology 130 13i 514-517 1083
10. Barbalias GA, Prostatodynia or painful male urethral syndrome? Urology 36 (2), 146 153, 1990
11. Boyarsky S et al , A new look at bladder neck obstruction by the Food and Drug Administration regulators guide lines for investigation of benign prostatic hypertrophy. Transactions of the American Association of Genito-Urinary Surgeons 68 29 32. 1977
12. Di Tranpani D et al . Chronic prostatitis and prostatodynia Ultrasonographic alterations of the prostate, bladder neck seminal vesicles and periprostatic venous plexus European Urology 15 (3-4) 230 234,1988
13. Greenberg RN et al Chronic prostatitis Comments on infectious etiologies and antimicrobial treatment Prostate 6 141 445- 448. 1985
14. Habib F et al. Androgen metabolism in the epithelial and stromal components of the human hyperplastic prostate Journal of Endocrinology 91, 23-32. 1981
15. Hinman F jr (ed). Benign prostatic hypertrophy Springer Verlag New York Heidelberg Berlin 1983
16. Ireton RC, Berger RE, Prostatitis and epididymitis Urologic Clinics of North America 11 11) 83-94 1984
17. Krieger JN et al Diagnostic considerations and interpretation of microbiological findings of evaluation of chronic prostatitis a Journal of Clinical Microbiology 27 110). 2240 2244, 1989
18. Lancet. Medical treatment of benign prostatic hyperplasia. Lancet 1 1083-1084 1988
19. Orland SM et al . Prostatitis. prostatosis. and prostatodynia. Urology 25 (5). 439-459 1985
20. Riedasch Get al Antibody-coated bacteria in ejaculate in bacterial prostatitis Urology 23 (3) 252-255 1984
21. Shortliffe LM Prostatitis Still a diagnostic and therapeutic dilemma Western Journal of Medicine 139 (41 542-544 198
22. Thin RN Simmons PD. Chronic bacterial and non-bacterial prostatitis British Journal of Urology 55 15) 513-518 1983
23. Vahlensieck W Dworak 0. Abgrenzuog der rezidivierenden Prostatakongestion von dec cbronrschen Prostatitis (Deliminatiori between recurrent congestion of the prostate and chronic prostatitis Helvetica Chirurgica Acta 555 (3). 293 296 1988
24. Vahlensieck W Rutishauser G (eCs). Benign prostme diseases. G Thieme-Verlag Stuttgart. New-York. 1992
25. Weidner W et al . Chlarnydia trachomatis in abacterial’ prostatitis Microbiologica . cytological and serological studies Urologia Internatonalis 28)3). 146-149.1983
26. Weidner W. Moderne Prostatitisdiagnostik Klinische und experimentelle Urologie 7 1-211 1984
27. Wilson JD The pathogenesis of benign prostatic hyperplasia American journal of Medicine 68 745-756.1980

Top of Page        Science FAQ Questions

last update: January 31, 2009

Lorem ipsum dolor sit amet, consetetur sadipscing elitr?
Lorem ipsum dolor sit amet, consetetur sadipscing elitr?

Top of Page        Science FAQ Questions

Top of Page        Science FAQ Questions